Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: Further evidence supporting somatostatin's involvement in GH suppression

Metabolism: Clinical and Experimental

Volumn 46, Issue 11, 1997, Pages 1305-1311

  Goni M J ^a   Monreal, M ^a   Goni F ^a   Sopena, M ^a   Gil, M J ^a   Moncada, E ^a   Salvador, J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCAGON; HYDROCORTISONE; INSULIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; PLACEBO; SERMORELIN; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THYROTROPIN RELEASE;

EID: 0030784772     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90235-3     Document Type: Article

References (31)

1. Hansen AP, Johansen K: Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normal and juvenile diabetics. Diabetologia 6:27-33, 1970
2. Hansen AP: Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 49:1467-1478, 1970
3. Dasmahapatra A, Urdanivia E, Cohen M: Growth hormone response to thyrotropin releasing hormone in diabetes. J Clin Endocrinol Metab 52:859-862, 1981
4. Press M, Tamborlane WV, Thorner MO, et al: Pituitary response to growth hormone-releasing factor in diabetes. Failure of glucose-mediated suppression. Diabetes 33:804-806, 1984
5. Topper EJ, Gertner S, Amiel M, et al: Deranged alpha-adrenergic regulation of growth hormone secretion in poorly controlled diabetes: Reversal of the exaggerated response to clonidine after continuous subcutaneous infusion. Pediatr Res 19:534-536, 1985
6. Lanes R, Recker B, Fort P, et al: Impaired somatomedin generation test in children with insulin dependent diabetes mellitus. Diabetes 34:156-160, 1985
7. Dieguez C, Page MD, Scanlon MF: Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol (Oxf) 28:109-143, 1988
8. Casanueva FF, Villanueva L, Dieguez C, et al: Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level. J Clin Endocrinol Metab 62:186-191, 1986
9. Locatelli V, Torsello A, Readelli M, et al: Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: Evidence for mediation by somatostatin. J Endocrinol 111:271-278, 1986
10. Page MD, Koppeschaar HPF, Dieguez C, et al: Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep related growth hormone release in young patients with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 26:355-359, 1987
11. Pietschmann P, Schernthaner G, Luger A: Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone (1-44)-induced GH secretion in acromegaly and type I diabetes mellitus. J Clin Endocrinol Metab 63:389-393, 1986
12. Ara J, Kang S, Creagh FM, et al: Modulation of glucose and growth hormone responses to meals and exercise in type 1 diabetes by cholinergic muscarinic blockade. Diabetic Med 11:92-97, 1994
13. Siler TM, Yen SSC, Vale W, et al: Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 38:742-745, 1974
14. Weeke J, Hansen AP, Lundbaek K: Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men. J Clin Endocrinol Metab 41:168-171, 1975
15. Salvador J, Dieguez C, Scanlon MF: The circadian rhythms of thyrotrophin and prolactin secretion. Cronobiol Int 5:85-93, 1988
16. Cohen RM, Ablanalp WA: Resistance of growth hormone secretion to somatostatin in men with type I diabetes mellitus. Diabetes 40:1251-1258, 1991
17. Plewe G, Nölken G, Krause U, et al: Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol 21:166-169, 1986 (suppl 119)
18. Orskov H, Flyvbjerg A, Frystyk J, et al: Octreotide and diabetes: Theoretical and experimental aspects. Metabolism 41:66-71, 1992 (suppl 2)
19. Coiro V, Passeri M, Gardini E, et al: Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects. Metabolism 39:668-675, 1990
20. Hummer R, Koss FW: The pharmacokinetic profile of pirenzepine. Scand J Gastroenterol 14:1-20, 1979 (suppl 57)
21. Edge JA, Matthews DR, Dunger DB: The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 33:729-737, 1990
22. Campbell PJ, Boli GB, Gerich JE: Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog. Metabolism 37:34-37, 1988
23. Miller JD, Wright NM, Lester SE, et al: Spontaneous and stimulated growth hormone release in adolescents with type I diabetes mellitus: Effects of metabolic control. J Clin Endocrinol Metab 75:1087-1091, 1992
24. Ismail IS, Scanlon MF, Peters JR: Effects of ambient glycemic state on growth hormone responsiveness in insulin-dependent diabetes. Clin Endocrinol (Oxf) 35:499-504, 1991
25. Davies RR, Miller M, Turner SJ, et al: Effects of somatostatin analogue SMS 201-995 in non-insulin-depenclent diabetes. Clin Endocrinol (Oxf) 25:739-747, 1986
26. Coiro V, Marchesi C, De Ferri A, et al: Pirenzepine inhibits growth hormone, but not thyrotropin response to thyrotropin-releasing hormone in patients with endogenous depression. Psychoneuroendocrinology 12:313-317, 1987
27. Volpi R, Chiodera P, Cerri L, et al: Cholinergic mediation of growth hormone secretion induced by thyrotropin-releasing hormone in cirrhotic patients. Acta Endocrinol (Copenh) 114:603-608, 1987
28. Ghigo E, Arvat E, Mazza E, et al: Failure of pyridostigmine to increase both basal and GHRH-induced GH secretion in the night. Acta Endocrinol (Copenh) 122:37-40, 1990
29. Williams TC, Kelijman M, Crelin WC, et al: Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 66:39-45, 1988
30. Spoudeas HA, Matthews DR, Brook CGD, et al: The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli. J Clin Endocrinol Metab 75:453-458, 1992
31. Llorente I, Lizcano F, Alvarez R, et al: Cholinergic modulation of spontaneous hypothalamic-pkuitary-adrenal activity and its circadian variation in man. J Clin Endocrinol Metab 81:2902-2907, 1996